Aptamer-mediated codelivery of doxorubicin and NF-κB decoy enhances chemosensitivity of pancreatic tumor cells

Molecular Therapy Nucleic Acids

Volumn 4, Issue 4, 2015, Pages e235-

  Porciani, David ^a,b   Tedeschi, Lorena ^c   Marchetti, Laura ^a   Citti, Lorenzo ^c   Piazza, Vincenzo ^b   Beltram, Fabio ^a,b   Signore, Giovanni ^b  

^a SCUOLA NORMALE SUPERIORE   (Italy)

^b CENTER FOR NANOTECHNOLOGY INNOVATION NEST   (Italy)

^c INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Aptamer decoy chimera; Aptamer mediated codelivery; NF kB decoy; Nucleic acid aptamer; Targeted delivery

Indexed keywords

APTAMER; DEOXYRIBONUCLEASE; DOUBLE STRANDED DNA; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OLIGONUCLEOTIDE; RNA; TRANSFERRIN RECEPTOR; X LINKED INHIBITOR OF APOPTOSIS;

3T3 CELL LINE; ALKALINITY; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL COMPARTMENTALIZATION; CELL SURVIVAL; CELL VIABILITY; CELL VIABILITY ASSAY; CHEMICAL STRUCTURE; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONSENSUS SEQUENCE; CONTROLLED STUDY; DESORPTION; DNA HYBRIDIZATION; DRUG BINDING SITE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; EMBRYO; ENDOCYTOSIS; ENDOSOME; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE ACTIVATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; INCUBATION TIME; INTERNALIZATION; LYSOSOME; MOUSE; NONHUMAN; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SYNTHESIS; TUMOR MICROENVIRONMENT;

EID: 84958164820     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2015.9     Document Type: Article

References (47)

1. Nakanishi, C and Toi, M (2005). Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5: 297-309.
2. Yu, MK, Park, J and Jon, S (2012). Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2: 3-44.
3. Ellington, AD and Szostak, JW (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-822.
4. Tuerk, C and Gold, L (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249: 505-510.
5. Keefe, AD, Pai, S and Ellington, A (2010). Aptamers as therapeutics. Nat Rev Drug Discov 9: 537-550.
6. Hicke, BJ, Stephens, AW, Gould, T, Chang, YF, Lynott, CK, Heil, J et al. (2006). Tumor targeting by an aptamer. J Nucl Med 47: 668-678.
7. Bagalkot, V, Farokhzad, OC, Langer, R and Jon, S (2006). An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl 45: 8149-8152.
8. Meng, L, Yang, L, Zhao, X, Zhang, L, Zhu, H, Liu, C et al. (2012). Targeted delivery of chemotherapy agents using a liver cancer-specific aptamer. PLoS One 7: e33434.
9. Zhu, G, Zheng, J, Song, E, Donovan, M, Zhang, K, Liu, C et al. (2013). Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics. Proc Natl Acad Sci USA 110: 7998-8003.
10. Zhang, X, Chabot, D, Sultan, Y, Monreal, C and DeRosa, MC (2013). Target-molecule-triggered rupture of aptamer-encapsulated polyelectrolyte microcapsules. ACS Appl Mater Interfaces 5: 5500-5507.
11. Daniels, TR, Delgado, T, Rodriguez, JA, Helguera, G and Penichet, ML (2006). The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 121: 144-158.
12. Daniels, TR, Delgado, T, Helguera, G and Penichet, ML (2006). The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol 121: 159-176.
13. Porciani, D, Signore, G, Marchetti, L, Mereghetti, P, Nifosì, R and Beltram, F (2014). Two interconvertible folds modulate the activity of a DNA aptamer against transferrin receptor. Mol Ther Nucleic Acids 3: e144.
14. Wilner, SE, Wengerter, B, Maier, K, de Lourdes Borba Magalhães, M, Del Amo, DS, Pai, S et al. (2012). An RNA alternative to human transferrin: a new tool for targeting human cells. Mol Ther Nucleic Acids 1: e21.
15. Chen, CH, Dellamaggiore, KR, Ouellette, CP, Sedano, CD, Lizadjohry, M, Chernis, GA et al. (2008). Aptamer-based endocytosis of a lysosomal enzyme. Proc Natl Acad Sci USA 105: 15908-15913.
16. Menna, P, Salvatorelli, E and Minotti, G (2007). Doxorubicin degradation in cardiomyocytes. J Pharmacol Exp Ther 322: 408-419.
17. Mi, J, Zhang, X, Rabbani, ZN, Liu, Y, Reddy, SK, Su, Z et al. (2008). RNA aptamer-targeted inhibition of NF-κB suppresses non-small cell lung cancer resistance to doxorubicin. Mol Ther 16: 66-73.
18. Bottero, V, Busuttil, V, Loubat, A, Magné, N, Fischel, JL, Milano, G et al. (2001). Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells. Cancer Res 61: 7785-7791.
19. Cao, LP, Song, JL, Yi, XP and Li, YX (2013). Double inhibition of NF-κB and XIAP via RNAi enhances the sensitivity of pancreatic cancer cells to gemcitabine. Oncol Rep 29: 1659-1665.
20. Sims, JT, Ganguly, SS, Bennett, H, Friend, JW, Tepe, J and Plattner, R (2013). Imatinib reverses doxorubicin resistance by affecting activation of S TAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1. PLoS One 8: e55509.
21. Zhao, N, Wang, R, Zhou, L, Zhu, Y, Gong, J and Zhuang, SM (2014). MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3. Mol Cancer 13: 35.
22. Gilmore, TD and Herscovitch, M (2006). Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene 25: 6887-6899.
23. Shimizu, H, Nakagami, H, Tsukamoto, I, Morita, S, Kunugiza, Y, Tomita, T et al. (2006). NFkappaB decoy oligodeoxynucleotides ameliorates osteoporosis through inhibition of activation and differentiation of osteoclasts. Gene Ther 13: 933-941.
24. De Stefano, D, De Rosa, G, Maiuri, MC, Ungaro, F, Quaglia, F, Iuvone, T et al. (2009). Oligonucleotide decoy to NF-kappaB slowly released from PLGA microspheres reduces chronic inflammation in rat. Pharmacol Res 60: 33-40.
25. Chaires, JB, Herrera, JE and Waring, MJ (1990). Preferential binding of daunomycin to 5'ATCG and 5'ATGC sequences revealed by footprinting titration experiments. Biochemistry 29: 6145-6153.
26. Zadeh, JN, Steenberg, CD, Bois, JS, Wolfe, BR, Pierce, MB, Khan, AR et al. (2011). NUPACK: Analysis and design of nucleic acid systems. J Comput Chem 32: 170-173.
27. Kim, D, Jeong, YY and Jon, S (2010). A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano 4: 3689-3696.
28. Camp, ER, Wang, C, Little, EC, Watson, PM, Pirollo, KF, Rait, A et al. (2013). Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther 20: 222-228.
29. Boyacioglu, O, Stuart, CH, Kulik, G and Gmeiner, WH (2013). Dimeric DNA aptamer complexes for high-capacity-targeted drug delivery using pH-sensitive covalent linkages. Mol Ther Nucleic Acids 2: e107.
30. Bonmati-Carrion, MA, Alvarez-Sánchez, N, Hardeland, R, Madrid, JA and Rol, MA (2013). A comparison of B16 melanoma cells and 3T3 fibroblasts concerning cell viability and ROS production in the presence of melatonin, tested over a wide Range of Concentrations. Int J Mol Sci 14: 3901-3920.
31. Kratz, F, Beyer, U, Roth, T, Tarasova, N, Collery, P, Lechenault, F et al. (1998). Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy. J Pharm Sci 87: 338-346.
32. Mo, R, Jiang, T, DiSanto, R, Tai, W and Gu, Z (2014). ATP-triggered anticancer drug delivery. Nat Commun 5: 3364.
33. Inoue, S, Setoyama, Y and Odaka, A (2014). Doxorubicin treatment induces tumor cell death followed by immunomodulation in a murine neuroblastoma model. Exp Ther Med 7: 703-708.
34. Vermes, I, Haanen, C, Steffens-Nakken, H and Reutelingsperger, C (1995). A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184: 39-51.
35. Carlo, R and Ildo, N (2006). Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 1: 1458-1461.
36. You, J, Zhang, G and Li, C (2010). Exceptionally high payload of doxorubicin in hollow gold nanospheres for near-infrared light-triggered drug release. ACS Nano 4: 1033-1041.
37. Wu, C, Han, D, Chen, T and Peng, L (2013). Building a multifunctional aptamer-based DNA nanoassembly for targeted cancer therapy. J Am Chem Soc 135: 18644-18650.
38. Cooper, JA Jr, Parks, JM, Carcelen, R, Kahlon, SS, Sheffield, M and Culbreth, R (2000). Attenuation of interleukin-8 production by inhibiting nuclear factor-kappaB translocation using decoy oligonucleotides. Biochem Pharmacol 59: 605-613.
39. Giannetti, A, Citti, L, Domenici, C, Tedeschi, L, Baldini, F, Wabuyele, MB, et al. (2006). FRET-based protein-DNA binding assay for detection of active NF-κB. Sensors Actuators B Chem 113: 649-654.
40. Yang, J, Chen, H, Vlahov, IR, Cheng, JX and Low, PS (2006). Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. Proc Natl Acad Sci USA 103: 13872-13877.
41. Shibuya, T, Takei, Y, Hirose, M, Ikejima, K, Enomoto, N, Maruyama, A et al. (2002). A double-strand decoy DNA oligomer for NF-kappaB inhibits TNFalpha-induced ICAM-1 expression in sinusoidal endothelial cells. Biochem Biophys Res Commun 298: 10-16.
42. Esposito, CL, Cerchia, L, Catuogno, S, De Vita, G, Dassie, JP, Santamaria, G et al. (2014). Multifunctional aptamer-miRNA conjugates for targeted cancer therapy. Mol Ther 22: 1151-1163.
43. Zhou, J, Bobbin, ML, Burnett, JC and Rossi, JJ (2012). Current progress of RNA aptamer-based therapeutics. Front Genet 3: 234.
44. Boulares, AH, Yakovlev, AG, Ivanova, V, Stoica, BA, Wang, G, Iyer, S et al. (1999). Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 274: 22932-22940.
45. Lopes, RB, Gangeswaran, R, McNeish, IA, Wang, Y and Lemoine, NR (2007). Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy. Int J Cancer 120: 2344-2352.
46. Bednarski, BK, Baldwin, AS Jr and Kim, HJ (2009). Addressing reported proapoptotic functions of NF-kappaB: targeted inhibition of canonical NF-kappaB enhances the apoptotic effects of doxorubicin. PLoS One 4: e6992.
47. Tedeschi, L, Citti, L and Domenici, C (2005). An integrated approach for the design and synthesis of oligonucleotide probes and their interfacing to a QCM-based RNA biosensor. Biosens Bioelectron 20: 2376-2385.